Researchers find increase in off-label use of hemophilia drug

04/19/2011 | U.S. News & World Report

Stanford University researchers said hospital use of recombinant factor 7a, an expensive hemophilia drug, increased 140 times in 2008 compared with 2000. Off-label use, such as during heart surgery or treating trauma, made up most of the increase. The drug was used in patients with hemophilia 4% of the time, according to a study published in Annals of Internal Medicine. Off-label use can increase the risk of heart attack and stroke because it raises blood-clot risk, the researchers said.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ